Open AccessThe consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib
Author(s) -
I.L. Shlivko,
Oksana Garanina,
Е. В. Артамонова,
Inna P. Ganshina,
Л. Г. Жукова,
Irina Koroleva,
А. В. Миченко,
T. Yu. Semiglazova,
Д. А. Филоненко
Publication year - 2021
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/18151434.2021.4.201275
Subject(s) - rash , medicine , breast cancer , oncology , adverse effect , metastatic breast cancer , population , dermatology , clinical trial , cancer , environmental health
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a poor prognostic factor for HR+ HER2- metastatic breast cancer. Alpelisib demonstrates efficacy in patients with PIK3CA mutation, but treatment might be associated with adverse events that include rash. All-grade rash was reported in 35.6% patients in SOLAR-1 trial (n=284). According to the published real-world data, for Russian population (n=19) all-grade rash was reported for 37% patients. The consensus contains practical recommendation on management of patients with rash of different grade.